A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma In Vitro and In Vivo is a research paper published in Cancers (2025). On theSindex it has a DataRank of 0.208. It has been cited 3 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.208
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →University of Arizona Cancer Center
Grant: P30CA023074
National Institutes of Health
Grant: 2P30CA023074-41
University of Arizona Cancer Center - Cancer Center Support Grant
National Institutes of Health
Grant: 1R01CA277493-01
Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic Malignancies
FWCI
2.15
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals